CTOs on the Move

Juventas Therapeutics

www.juventasinc.com

 
Juventas Therapeutics is a private clinical-stage company developing novel therapies for ischemic cardiovascular disease. The company`s lead product` JVS-100` is a non-viral plasmid that encodes for stromal cell-derived factor-1 (SDF-1). SDF-1 has been shown to significantly increase end-organ function following tissue injury by promoting cell survival` recruiting endogenous stem cells to the damaged region` and promoting new blood vessel growth. The SDF-1 repair pathway is well conserved throughout end-organ systems providing the opportunity to impact a broad range of diseases. Target cardiovascular clinical indications address large markets with high unmet medical need and significant market potential. Juventas is currently enrolling ...
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million
  • www.juventasinc.com
  • 3615 Superior Avenue Suite 4403C
    Cleveland, OH USA 44114
  • Phone: 216.273.4000
  • Fax: 216.359.0099

Executives

Name Title Contact Details

Funding

Juventas Therapeutics raised $14M on 05/13/2015

Similar Companies

Geltor

Geltor is the bio-design company that makes the world`s most advanced proteins for consumers, with a focus on unique functionality and sustainability.

Bayer Healthcare Pharmacuticals

Committed to developing novel diagnostics and therapeutics that address unmet medical needs, Berlex, Inc., a U.S. affiliate of Schering AG, Germany (NYSE:SHR), develops and markets diagnostic imaging agents, treatments in the areas of female healthcare

Groninger USA

Groninger USA is a Charlotte, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Conversant Biologics

Conversant Biologics is a Huntsville, AL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

C2N Diagnostics

C2N Diagnostics is a privately-held biotechnology company based in St. Louis, Missouri. We focus on the development of clinical diagnostics and therapeutics for serious brain disorders, with a particular emphasis on Alzheimer`s disease and related forms of progressive neurodegeneration.